Hemab Therapeutics Holdings, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Hemab Therapeutics announced strong Q2 2026 results with significant pipeline progress, including new data for HMB-002 and HMB-003, and advancement of sutacimig towards Phase 3 trials, bolstered by a substantial cash position post-IPO.